Why Maharashtra FDA Flagged Cadila Pharmaceuticals for Branding Concerns
The Maharashtra FDA has ordered a recall of Cadila Pharmaceuticals' 'Aciloc' range after seizing INR 2.45 crore worth of stock. The action follows concerns that the company used deceptively similar branding for products containing different active ingredients, posing a risk of medication errors. The FDA has prohibited the sale of 'Plus' variants to ensure patient safety.
The Maharashtra Food and Drug Administration (FDA) has ordered a total market recall of several variants of the "Aciloc" brand manufactured by Cadila Pharmaceuticals Ltd., citing concerns over deceptive branding and potential medication errors. The regulator has also prohibited the sale and distribution of these products across the state, seizing stock valued at approximately INR 2.45 crore.
The regulatory action follows a routine inspection in Amravati, which revealed that while the company was originally licensed to manufacture Aciloc 150 and Aciloc 300 using Ranitidine as the active pharmaceutical ingredient (API), it recently introduced "Aciloc 150+" and "Aciloc 300+" variants. These newer versions replaced Ranitidine with Famotidine- a chemically distinct ingredient - but retained near-identical label artwork and branding, merely adding a "plus" symbol. Maharashtra FDA Mandates Free Potable Water in All Hotels and Restaurants.
Public Health Risks and Regulatory Violation
The FDA emphasised that marketing products with different active ingredients under deceptively similar brand names creates a significant risk of confusion among doctors, pharmacists, and patients. Because the older Ranitidine-based products and the new Famotidine-based "Plus" variants were being sold simultaneously, the administration warned that this could lead to the dispensing or consumption of the wrong medication.
FDA Commissioner Tukaram Mundhe underscored the gravity of the situation, stating, "Any confusion caused by a medicine's brand name among patients, doctors, or pharmacists, leading to the dispensing of the wrong medicine, is a matter of grave public health concern." He added, "Compliance with regulations governing drug branding, labelling, and marketing, while ensuring patient safety, must remain paramount. Safe medicines are a fundamental right of every citizen, and safeguarding that right is our highest responsibility."
Recall and Enforcement Details
Following the inspection findings, the FDA conducted swift raids on July 9 and 10 at the company’s Carrying and Forwarding Agent (CFA) warehouses in Pune, Nagpur, and Bhiwandi (Thane). The seized stock, totalling INR 2,45,37,490, has been officially prohibited from sale. The FDA has issued the following directives:
- Immediate Recall: The company must recall all available stock of Aciloc 150, Aciloc 150 Plus, Aciloc 300, and Aciloc 300 Plus from the market.
- Sales Ban: The sale and distribution of Aciloc 150 Plus and Aciloc 300 Plus are strictly prohibited.
- Advisory: Medical professionals and citizens are urged to verify the active pharmaceutical ingredient on labels before prescribing, dispensing, or consuming these medicines. Why Maharashtra FDA Banned Compulsory Hospital Pharmacy Purchases.
The administration noted that further legal action under the Drugs and Cosmetics Act, 1940, will be determined based on the ongoing investigation into the company’s compliance lapses. Patients who encounter any uncertainty or suspicious medication packaging are encouraged to report the matter to the state FDA.
(The above story first appeared on LatestLY on Jul 12, 2026 03:18 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
